Commodore Capital LP
- SEC CIK
- 0001831942
- 最新申報
- 2026/8/14
2024 年第 1 季持倉
持倉截至 2024/3/31，2024/5/15 申報。只含多頭部位，變化是跟 2023 年第 4 季比股數。
- 持股檔數
- 39
- 較 2023 年第 4 季 +7
- 總值
- $15.0 億
- 較 2023 年第 4 季 +$3.51 億 (+30.7%)
| 證券 | 類別 | 股數 | 市值 | 佔組合 % | 股數變化 | 動作 | 紀錄 |
|---|---|---|---|---|---|---|---|
| MRUSMerus N.V. | COM | 4,360,000 | $1.96 億 | 13.1% | −387,373−8.2% | 減碼 | 歷史 |
| VERAVera Therapeutics, Inc. | CL A | 3,165,000 | $1.36 億 | 9.1% | −2,285,000−41.9% | 減碼 | 歷史 |
| NUVLNuvalent, Inc. | COM | 1,487,756 | $1.12 億 | 7.5% | +156,719+11.8% | 加碼 | 歷史 |
| XENEXenon Pharmaceuticals Inc. | COM | 2,167,793 | $9,332 萬 | 6.2% | 00.0% | 不變 | 歷史 |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,884,084 | $7,146 萬 | 4.8% | 00.0% | 不變 | 歷史 |
| ELVNEnliven Therapeutics, Inc. | COM | 3,973,245 | $6,989 萬 | 4.7% | +1,071,429+36.9% | 加碼 | 歷史 |
| PCVXVaxcyte, Inc. | COM | 860,000 | $5,875 萬 | 3.9% | −240,000−21.8% | 減碼 | 歷史 |
| DFTXDefinium Therapeutics, Inc. | Stock | 5,833,333 | $5,483 萬 | 3.7% | +5,833,333 | 新進 | 歷史 |
| ALPNAlpine Immune Sciences, Inc. | COM | 1,375,000 | $5,451 萬 | 3.6% | −235,000−14.6% | 減碼 | 歷史 |
| ARVNArvinas, Inc. | COM | 1,275,000 | $5,263 萬 | 3.5% | +275,000+27.5% | 加碼 | 歷史 |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 1,050,000 | $4,550 萬 | 3.0% | −500,000−32.3% | 減碼 | 歷史 |
| COGTCogent Biosciences, Inc. | COM | 6,425,000 | $4,318 萬 | 2.9% | +858,974+15.4% | 加碼 | 歷史 |
| PHVSPharvaris N.V. | COM | 1,725,000 | $3,986 萬 | 2.7% | +925,000+115.6% | 加碼 | 歷史 |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 866,468 | $3,637 萬 | 2.4% | +164,501+23.4% | 加碼 | 歷史 |
| NKTXNkarta, Inc. | COM | 3,165,000 | $3,421 萬 | 2.3% | +435,000+15.9% | 加碼 | 歷史 |
| VRDNViridian Therapeutics, Inc. | COM | 1,934,653 | $3,388 萬 | 2.3% | +10,579+0.5% | 加碼 | 歷史 |
| CELCCelcuity Inc. | COM | 1,555,954 | $3,361 萬 | 2.2% | −198,750−11.3% | 減碼 | 歷史 |
| KURAKura Oncology, Inc. | COM | 1,525,000 | $3,253 萬 | 2.2% | +276,938+22.2% | 加碼 | 歷史 |
| CCCCC4 Therapeutics, Inc. | COM STK | 3,410,384 | $2,786 萬 | 1.9% | −389,616−10.3% | 減碼 | 歷史 |
| ORICOric Pharmaceuticals, Inc. | COM | 2,000,000 | $2,750 萬 | 1.8% | +2,000,000 | 新進 | 歷史 |
| ABVXAbivax S.A. | SPONSORED ADS | 1,895,003 | $2,710 萬 | 1.8% | 00.0% | 不變 | 歷史 |
| CATXPerspective Therapeutics, Inc. | COM | 21,052,631 | $2,505 萬 | 1.7% | +21,052,631 | 新進 | 歷史 |
| IMVTImmunovant, Inc. | COM | 750,990 | $2,426 萬 | 1.6% | −249,010−24.9% | 減碼 | 歷史 |
| KYTXKyverna Therapeutics, Inc. | COM | 912,189 | $2,266 萬 | 1.5% | +912,189 | 新進 | 歷史 |
| ENGNenGene Therapeutics Inc. | COM | 1,250,000 | $2,119 萬 | 1.4% | +1,250,000 | 新進 | 歷史 |
| APGEApogee Therapeutics, Inc. | COM | 290,000 | $1,927 萬 | 1.3% | +40,000+16.0% | 加碼 | 歷史 |
| CABACabaletta Bio, Inc. | COM | 1,100,000 | $1,877 萬 | 1.3% | −800,000−42.1% | 減碼 | 歷史 |
| AUTLAutolus Therapeutics plc | SPON ADS | 2,300,000 | $1,467 萬 | 1.0% | +2,300,000 | 新進 | 歷史 |
| THRDThird Harmonic Bio, Inc. | COM | 1,250,000 | $1,180 萬 | 0.8% | +543,294+76.9% | 加碼 | 歷史 |
| NGNENeurogene Inc. | COM | 200,000 | $1,018 萬 | 0.7% | +200,000 | 新進 | 歷史 |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 657,333 | $929.5 萬 | 0.6% | −342,667−34.3% | 減碼依 1 比 10 拆股換算 | 歷史 |
| VTGNVistagen Therapeutics, Inc. | COM | 1,575,000 | $831.6 萬 | 0.6% | 00.0% | 不變 | 歷史 |
| SNDXSyndax Pharmaceuticals Inc | COM | 318,851 | $758.9 萬 | 0.5% | +318,851 | 新進 | 歷史 |
| SLNOSoleno Therapeutics Inc | COM | 169,533 | $725.6 萬 | 0.5% | −530,467−75.8% | 減碼 | 歷史 |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 500,000 | $520.0 萬 | 0.3% | +500,000 | 新進 | 歷史 |
| MGNXMacrogenics Inc | COM | 295,020 | $434.3 萬 | 0.3% | +295,020 | 新進 | 歷史 |
| ACETAdicet Bio, Inc. | COM | 1,374,320 | $323.0 萬 | 0.2% | +1,374,320 | 新進 | 歷史 |
| SABSSAB Biotherapeutics, Inc. | COM NEW | 183,174 | $83.2 萬 | 0.1% | 00.0% | 不變依 1 比 10 拆股換算 | 歷史 |
| DBVTDBV Technologies S.A. | SPONSORED ADR | 92,687 | $6.94 萬 | <0.1% | 00.0% | 不變 | 歷史 |
2023 年第 4 季之後清倉（4 檔）
2023 年第 4 季季末還持有、這份申報已經沒有的部位。